Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.
IPO Year: 2018
Exchange: NASDAQ
Website: xerispharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/11/2024 | $3.00 | Overweight → Neutral | Piper Sandler |
| 3/28/2024 | $5.00 | Outperform | Oppenheimer |
| 8/28/2023 | $4.50 | Buy | Craig Hallum |
| 10/21/2022 | $4.00 | Buy | Jefferies |
| 4/28/2022 | $6.50 | Buy | Craig Hallum |
| 2/16/2022 | $8.00 → $6.00 | Outperform | SVB Leerink |
| 12/31/2021 | $6.00 → $8.00 | Outperform | SVB Leerink |
| 12/31/2021 | $4.25 → $5.40 | Buy | HC Wainwright & Co. |
| 11/17/2021 | $6.00 | Outperform | SVB Leerink |
| 10/29/2021 | $4.00 | Buy | HC Wainwright & Co. |
First concentrated, ready-to-dilute liquid glucagon available for growing procedural gastroenterology market American Regent to commercialize GVOKE VialDx™ Availability is expected in the third quarter of 2025 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its supplemental new drug application (sNDA) of Gvoke VialDx™ has received U.S Food and Drug Administration (FDA) approval for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult pa
Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year Recorlev® revenue more than doubled versus prior year and grew 28% in the fourth quarter sequentially Ended Q4 with over $71M in cash, generating $2M in cash in the fourth quarter Provides full-year 2025 total revenue guidance of $255M-$275M, representing a growth of over 30% at the mid-point of the range Hosting conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today annou
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full-year 2024 financial results and provide 2025 financial guidance before the open of the U.S. financial markets on Thursday, March 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadsh
Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision and strategic direction for the Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions, reporting to John Shannon, X
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will take part in the following events: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 1x1 meetings and fireside chat February 12, 2025 at 1:20 pm ET Leerink Global Healthcare Conference, Miami, FL 1x1 meetings and fireside chat on March 10, 2025 at 8:40 am ET Barclays 27th Annual Global Healthcare Conference, Miami, FL 1x1 meetings only on March 11, 2025 Please check with each co
Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation CHICAGO and ARLINGTON, Va., Jan. 21, 2025 /PRNewswire/ -- The American Diabetes Association® (ADA) and Xeris Pharmaceuticals® (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to announce a multi-year strategic partnership to reinforce the importance of prescribing glucagon, preferably ready-to-use, for all individuals with diabetes who are treated with insulin and/or insulin secretagogues or those at high risk of hypoglycemia (low blood glucose, also called low blood sugar), in line with
Full-year 2024 total revenue projected to be $203 million, exceeding previous guidance of $198-$202 million Year-end 2024 cash position expected to be over $71 million, generating positive cash flow in the fourth quarter Recorlev® net revenue Q4 2024 anticipated to increase by approximately $5 million or 28% sequentially 2024 financial results and 2025 outlook expected on March 6, 2025 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) today announced it expects to generate total 2024 revenue of $203 million, which will exceed previously announced 2024 total revenue guidance of $198 million to $202 million. The Company also anticipates ending 2024 with over $71 million in cash, cash equiv
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on January 2, 2025, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 181,500 shares of its common stock to 19 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xer
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 8:00am Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Xeris' Investor Relations website at www.xerispharma.com. A replay of the webcast will be available for 30 days. About Xeris Xeris (NASDAQ:XERS) is a growth-oriented biopharmaceutical company co
Achieved record total revenue of $54.3M including record product revenue of $52.9M Product revenue increased 27% versus prior year and 14% over the prior quarter Ended Q3 with $69.4M in cash, cash equivalents and short-term investments Raises full-year guidance of total net revenue to $198M-$202M and tightens year-end cash to $68M-$72M Hosting conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30,
144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
10-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
10-Q - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
S-8 - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
10-Q - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
Piper Sandler downgraded Xeris Biopharma from Overweight to Neutral and set a new price target of $3.00
Oppenheimer initiated coverage of Xeris Biopharma with a rating of Outperform and set a new price target of $5.00
Craig Hallum initiated coverage of Xeris Biopharma with a rating of Buy and set a new price target of $4.50
Jefferies initiated coverage of Xeris Biopharma with a rating of Buy and set a new price target of $4.00
Craig Hallum initiated coverage of Xeris Biopharma with a rating of Buy and set a new price target of $6.50
SVB Leerink reiterated coverage of Xeris Biopharma Holdings with a rating of Outperform and set a new price target of $6.00 from $8.00 previously
SVB Leerink reiterated coverage of Xeris Biopharma Holdings with a rating of Outperform and set a new price target of $8.00 from $6.00 previously
HC Wainwright & Co. reiterated coverage of Xeris Biopharma Holdings with a rating of Buy and set a new price target of $5.40 from $4.25 previously
SVB Leerink initiated coverage of Xeris Biopharma Holdings with a rating of Outperform and set a new price target of $6.00
HC Wainwright & Co. initiated coverage of Xeris Biopharma Holdings with a rating of Buy and set a new price target of $4.00
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G/A - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G/A - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G/A - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G/A - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G - XERIS PHARMACEUTICALS INC (0001346302) (Subject)
SC 13G/A - XERIS PHARMACEUTICALS INC (0001346302) (Subject)
Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year Recorlev® revenue more than doubled versus prior year and grew 28% in the fourth quarter sequentially Ended Q4 with over $71M in cash, generating $2M in cash in the fourth quarter Provides full-year 2025 total revenue guidance of $255M-$275M, representing a growth of over 30% at the mid-point of the range Hosting conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today annou
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full-year 2024 financial results and provide 2025 financial guidance before the open of the U.S. financial markets on Thursday, March 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadsh
Achieved record total revenue of $54.3M including record product revenue of $52.9M Product revenue increased 27% versus prior year and 14% over the prior quarter Ended Q3 with $69.4M in cash, cash equivalents and short-term investments Raises full-year guidance of total net revenue to $198M-$202M and tightens year-end cash to $68M-$72M Hosting conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30,
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2024 financial results before the open of the U.S. financial markets on Friday, November 8, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=6c5018a9&confId=72180. Afte
Achieved revenue of $48.1M including record product revenue of $46.5M Total revenues increased 18% over the prior quarter and 26% over the same period prior year Ended Q2 with $77.6M in cash, cash equivalents and short-term investments Tightens full-year 2024 guidance: total net revenue to $190M-$200M and year-end cash balance to $60M-$75M John Shannon appointed CEO and Kevin McCulloch promoted to President and COO per the Company's long-standing succession plan Hosting conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing inno
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets on Thursday, August 8, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=44e9222b&confId=68537 Af
Q1 2024 Total Revenue of $40.6M – up 22% over Q1 2023 Tightening full-year 2024 total revenue guidance to $175M-$200M Ended Q1 with $87.4M in cash, cash equivalents, and short-term investments, lowered borrowing rate of Hayfin debt by 2.05% Entered into a worldwide license agreement for XeriJect® formulation of teprotumumab Announced an exclusive worldwide agreement with Beta Bionics for development of a new XeriSol™ formulation of glucagon for bi-hormonal pumps and pump systems Hosting conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets on Thursday, May 9, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=7144015a&confId=62782 Afte
Achieved Total Revenue of over $44M in the fourth quarter – a 34% increase from same period prior year and generated approximately $164M for the full year 2023, a 49% increase versus prior year Ended 2023 with over $72M in cash, cash equivalents, and short-term investments achieving cash flow positive of over $6M in the fourth quarter Entered into a worldwide license agreement for XeriJect® formulation of teprotumumab Refinanced and upsized Hayfin term loan to a lower overall cost of capital with additional capital available to invest for future growth Provides full-year 2024 guidance: total net revenue of $170M-$200M; year-end cash, cash equivalents, and short-term investments of $
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Wednesday, March 6, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results and provide full-year 2024 guidance. To pre-register for the conference call please use this link: Registration Link: https://www.netroadshow.com/events/login?sh
Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision and strategic direction for the Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions, reporting to John Shannon, X
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track record of its leadership team Q2 '24 total revenue is anticipated to exceed $47 million, representing more than 23% growth over last year Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced a CEO succession plan effective August 1, 20
Xeris Biopharma Holdings (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, appointed Ricki Fairley to its Board of Directors, increasing the size of the Board to nine members, on March 27, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230329005369/en/(Photo: Business Wire) "On behalf of our Board, we welcome Ricki and her wealth of insights and experiences, especially her passion for advocating on behalf of patients," said Paul R. Edick, Chairman and Chief Executive Officer of Xeris. "As
WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on December 30, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 38,250 shares, and restricted stock units for an aggregate of 35,100 shares, of its common stock to 7 new employee(s) under Xeris’ Inducement Equity Plan. Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
3 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)